Comparative Pharmacology
Head-to-head clinical analysis: BLISOVI FE 1 5 30 versus BLISOVI FE 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLISOVI FE 1 5 30 versus BLISOVI FE 1 20.
BLISOVI FE 1.5/30 vs BLISOVI FE 1/20
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Blisovi Fe 1.5/30 is a combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). It inhibits ovulation via suppression of gonadotropins (FSH and LH). Additionally, it increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial development, reducing implantation likelihood.
Combination of ethinyl estradiol, an estrogen, and desogestrel, a progestin, which inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation and altering cervical mucus and endometrial lining to reduce likelihood of fertilization and implantation.
Prevention of pregnancy
Prevention of pregnancyTreatment of heavy menstrual bleedingTreatment of acne (off-label)Treatment of dysmenorrhea (off-label)
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets (iron-free).
One tablet orally once daily for 21 days, followed by 7 days of placebo (iron-containing) tablets. Each active tablet contains 0.1 mg levonorgestrel and 20 mcg ethinyl estradiol.
None Documented
None Documented
Ethinyl estradiol: terminal half-life ~17 hours (range 13–27 h) with single dose; for norethindrone: ~8–11 hours. Clinical context: Steady-state achieved within ~7–10 days; contraceptive efficacy maintained with once-daily dosing.
Ethinyl estradiol: ~12-14 hours; norethindrone: ~7-8 hours; both allow once-daily dosing with steady-state reached within 7-10 days.
Ethinyl estradiol is metabolized primarily via CYP3A4; norethindrone is metabolized via reduction and conjugation, with some involvement of CYP3A4.
Ethinyl estradiol is metabolized primarily by CYP3A4; desogestrel is a prodrug converted to etonogestrel, which is metabolized by CYP2C9 and CYP3A4.
Renal: ~60% (ethinyl estradiol metabolites as glucuronide/sulfate conjugates, norethindrone metabolites). Fecal: ~40% (biliary excretion of conjugates, with some enterohepatic recirculation).
Renal: ~50-60% as metabolites; fecal: ~40-50% via biliary elimination; less than 10% unchanged in urine.
Ethinyl estradiol: ~97% bound to albumin (specifically to albumin, with some binding to SHBG). Norethindrone: ~61% bound to albumin, ~36% to SHBG. Iron: >99% bound to transferrin and ferritin. Folic acid: ~50–60% bound to plasma proteins (mainly albumin).
Ethinyl estradiol: ~97-98% bound (primarily albumin); norethindrone: ~93-95% bound (primarily albumin and SHBG).
Ethinyl estradiol: Vd ~2.7–4.8 L/kg (large, reflecting extensive tissue distribution). Norethindrone: Vd ~3.6–4.3 L/kg. Clinical meaning: large Vd indicates extensive extravascular binding (e.g., fat stores, steroid receptors). Iron: mainly in erythrocytes and reticuloendothelial system; Vd not typically reported. Folic acid: total body folate ~500–20,000 µg, with Vd ~0.6 L/kg (reflects distribution into tissues).
Ethinyl estradiol: ~2.5-4.0 L/kg; norethindrone: ~3.5-4.5 L/kg; large Vd indicates extensive tissue distribution.
Oral ethinyl estradiol: ~38–48% (first-pass metabolism). Norethindrone: ~64% (high first-pass). Folic acid: ~76–93% (dose-dependent; reduced when taken with food). Iron (ferrous fumarate): ~10–20% (varies with iron stores; increased in deficiency).
Oral: Ethinyl estradiol ~40-50% (first-pass metabolism); norethindrone ~50-70% (first-pass metabolism reduced with micronized formulation).
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential for iron accumulation.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (eGFR <30 mL/min/1.73 m²) or end-stage renal disease; use contraindicated due to potential for fluid retention and hypertension.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in mild to moderate hepatic impairment; monitor liver function.
Contraindicated in Child-Pugh Class B or C (moderate to severe hepatic impairment) due to reduced steroid clearance. Use with caution in Child-Pugh Class A; monitor liver function.
Not indicated for use in pediatric females before menarche. Safety and efficacy in adolescents have not been established; use is generally not recommended.
Use post-menarche. Standard dose: one tablet orally once daily for 21 days, then 7 days of placebo. Not indicated before menarche.
No specific dose adjustment for geriatric use. Consider increased risk of thromboembolic disorders and monitor accordingly.
Not indicated for use in postmenopausal women. No specific dose adjustment; efficacy and safety not established in geriatric population.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. The risk increases with age and with heavy smoking (≥15 cigarettes per day). Women over 35 who smoke should not use this product.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and number of cigarettes smoked, particularly in women over 35 years old.
["Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebrovascular accidents, myocardial infarction)","Hepatic neoplasia (benign and malignant)","Gallbladder disease","Hypertension","Carbohydrate and lipid metabolism effects","Headache/migraine","Irregular bleeding","Ectopic pregnancy risk if used for emergency contraception","Ocular lesions (retinal thrombosis)","Depression","Hereditary angioedema","Chloasma"]
["Increased risk of venous thromboembolism and arterial thrombosis","Increased risk of myocardial infarction and stroke, especially in smokers","Liver disease including hepatic adenoma and hepatocellular carcinoma","Hypertension","Gallbladder disease","Carbohydrate and lipid metabolism effects","Headache including migraine","Uterine bleeding irregularities","Depression","Hereditary angioedema","Chloasma","Ocular lesions (e.g., retinal thrombosis)"]
["Breast cancer or estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Known or suspected pregnancy","Liver disease or hepatic adenomas","Thrombotic disorders or history (DVT, PE, stroke, MI)","Major surgery with prolonged immobilization","Diabetes with vascular involvement","Uncontrolled hypertension","Migraine with aura (if age ≥35 or focal neurological symptoms)","Cigarette smoking in women ≥35 years"]
["Known or suspected pregnancy","Current or history of thromboembolic disorders (e.g., deep vein thrombosis, pulmonary embolism)","Cerebrovascular or coronary artery disease","Known or suspected breast cancer or other estrogen-sensitive neoplasia","Undiagnosed abnormal uterine bleeding","Liver tumors or active liver disease","Migraine with aura if age ≥35","Diabetes with vascular involvement","Uncontrolled hypertension","Major surgery with prolonged immobilization","Hypersensitivity to any component"]
Data Pending Review
Data Pending Review
Food does not significantly affect absorption of the hormonal components. Grapefruit juice may inhibit metabolism and increase estrogen levels; avoid large amounts. No specific dietary restrictions. Iron tablets may cause gastrointestinal upset; taking with food may help.
No specific food restrictions. May be taken with or without food. Grapefruit juice may increase ethinyl estradiol levels but not clinically significant. Avoid St. John's wort (reduces efficacy). Alcohol consumption is not contraindicated but may increase side effects like nausea or dizziness.
FDA Pregnancy Category X. Use is contraindicated in pregnant women because drospirenone/ethinyl estradiol can cause fetal harm. There is no indication for use in pregnancy. If pregnancy occurs during treatment, the drug should be discontinued immediately. Epidemiologic studies have not revealed an increased risk of birth defects in infants born to women who inadvertently used oral contraceptives early in pregnancy. However, drospirenone is a progestin with antiandrogenic activity, and animal studies have shown teratogenic effects including urogenital tract abnormalities at high doses.
Tri 1: No increased risk of birth defects in large cohort studies; however, combined hormonal contraceptives are contraindicated in pregnancy due to potential fetal harm from estrogen. Tri 2 & 3: No known teratogenicity; continuation after confirmed pregnancy not indicated.
Small amounts of contraceptive steroids have been identified in breast milk, with about 0.02% of the maternal dose of ethinyl estradiol transferred to the infant via milk. The M/P ratio for drospirenone is approximately 0.4–0.6. Combination oral contraceptives may reduce milk production and composition, and their use during breastfeeding is generally not recommended until weaning or at least 6 months postpartum if the infant is fully nursing. Alternative contraception methods are preferred during lactation.
Small amounts of ethinyl estradiol and norethindrone excreted in breast milk; no adverse effects reported. M/P ratio: Not available. Avoid use during breastfeeding if possible due to potential reduction in milk production.
There are no recommended dose adjustments for use during pregnancy because the drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, decreased protein binding, enhanced clearance) can reduce steroid hormone levels, potentially diminishing efficacy if used inadvertently. Therefore, if pregnancy occurs, discontinue the drug; no dose adjustment is applicable as the drug should not be used.
Contraindicated; discontinue if pregnancy occurs. No dose adjustment applicable in pregnancy.
Category C
Category C
BLISOVI FE 1.5/30 is a combination oral contraceptive containing ethinylestradiol and norethindrone acetate. It is primarily used for contraception and acne treatment. The iron component (ferrous fumarate) is not intended for contraceptive effect but to offset menstrual blood loss. Monitor for thromboembolic events, especially in smokers over 35. Use caution in patients with migraine with aura, hypertension, or liver disease. Drug interactions with rifampin, certain anticonvulsants, and St. John's wort may reduce contraceptive efficacy.
BLISOVI FE 1/20 is a combination oral contraceptive containing norethindrone acetate (1 mg) and ethinyl estradiol (20 mcg) with ferrous fumarate (75 mg) as an iron supplement in the placebo pills. The low estrogen dose may increase breakthrough bleeding risk, especially in the first few cycles. The ferrous fumarate tablets are not intended for contraceptive effect; ensure patients take active pills correctly. Missed pill management: if one active pill is missed, take as soon as remembered; if two or more active pills are missed, use backup contraception for 7 days and consider emergency contraception. Active pill color is pink; placebo pills are brown (ferrous fumarate). Contraindications: history of thromboembolic events, migraine with aura, liver disease, undiagnosed abnormal uterine bleeding, breast cancer, or pregnancy. Monitor for hypertension, depression, and cholestasis. Drug interactions: CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's wort) reduce efficacy; antibiotics may also reduce efficacy (except rifampin-like drugs, which are definite).
Take one tablet daily at the same time each day. The first 21 tablets are active hormones; the last 7 are iron tablets.If you miss a dose, refer to the package instructions. Missing pills increases risk of pregnancy.Do not smoke while taking this medication, especially if over 35 years old, due to increased risk of blood clots.Contact your healthcare provider if you experience severe headaches, chest pain, leg pain, vision changes, or jaundice.This medication does not protect against HIV or other sexually transmitted infections.Inform your doctor about all medications you are taking, including over-the-counter drugs and supplements.The iron tablets may cause black or dark stools; this is harmless.If you experience persistent vomiting or diarrhea, use additional contraception.
Take one pill daily at the same time, preferably in the evening to reduce nausea.The pill pack contains 21 active pink pills (hormonal) and 7 brown placebo pills (contain iron).You will have a withdrawal bleed during the placebo week, typically starting 2-3 days after the last active pill.If you miss a dose, refer to the package instructions: for one missed active pill, take it as soon as remembered; if more than one missed, use a backup method for 7 days.Inform your healthcare provider if you experience severe abdominal pain, chest pain, shortness of breath, headache, visual changes, or leg pain/swelling.Smoking increases the risk of serious cardiovascular side effects; avoid smoking, especially if over 35 years old.This medication does not protect against sexually transmitted infections; use condoms for prevention.The iron in placebo pills may cause dark stools; this is harmless.Store at room temperature away from moisture and heat.